GAIN THERAPEUTICS INC (GANX) Forecast, Price Target & Analyst Ratings

NASDAQ:GANX • US36269B1052

Current stock price

2.0495 USD
-0.57 (-21.77%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GAIN THERAPEUTICS INC (GANX).

Forecast Snapshot

Consensus Price Target

Price Target
$7.75
+ 278.24% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Mar 19, 2026
Period
Q4 / 2025
EPS Estimate
-$0.15
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.45%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$7.75
Upside
+ 278.24%
From current price of $2.05 to mean target of $7.75, Based on 11 analyst forecasts
Low
$5.05
Median
$8.16
High
$10.50

Price Target Revisions

1 Month
0.00%
3 Months
11.76%

Price Target Summary

11 Wall Street analysts provided a forecast for the next 12 months for GANX. The average price target is 7.75 USD. This implies a price increase of 278.24% is expected in the next year compared to the current price of 2.0495.
The average price target has been revised upward by 11.76% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

GANX Current Analyst RatingGANX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

GANX Historical Analyst RatingsGANX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
85.45%
GANX was analyzed by 11 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about GANX.
In the previous month the buy percentage consensus was at a similar level.
GANX was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-12-19HC Wainwright & Co.Reiterate Buy -> Buy
2025-10-15BTIGReiterate Buy -> Buy
2025-10-13HC Wainwright & Co.Reiterate Buy -> Buy
2025-10-07Maxim GroupMaintains Buy -> Buy
2025-09-08BTIGReiterate Buy -> Buy
2025-08-13Roth CapitalMaintains Buy -> Buy
2025-07-03HC Wainwright & Co.Reiterate Buy -> Buy
2025-05-19HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-28Chardan CapitalMaintains Buy -> Buy
2025-03-17HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-07ScotiaBankInitiate Sector Outperform
2024-12-24Roth MKMMaintains Buy -> Buy
2024-12-05Roth MKMInitiate Buy
2024-11-25HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-09HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-01HC Wainwright & Co.Reiterate Buy -> Buy
2024-09-03HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-09Chardan CapitalMaintains Buy -> Buy
2024-07-11HC Wainwright & Co.Reiterate Buy -> Buy
2024-07-02HC Wainwright & Co.Maintains Buy -> Buy
2024-05-31HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-28HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-15HC Wainwright & Co.Reiterate Buy -> Buy
2024-04-25HC Wainwright & Co.Reiterate Buy -> Buy
2024-04-23OppenheimerMaintains Outperform -> Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
Mar 19, 2026
Period
Q4 / 2025
EPS Estimate
-$0.15
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
-34.45%
Number of Analysts
7

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

GANX is expected to report earnings on 3/19/2026. The consensus EPS estimate for the next earnings is -0.15 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
GANX revenue by date.GANX revenue by date.
160K
433.33%		140K
-12.50%		55.2K
-60.57%
-100.00%		52.236M137.26M
162.77%		230.82M
68.16%		303.26M
31.38%		478.11M
57.66%
EBITDA
YoY % growth
GANX ebitda by date.GANX ebitda by date.
-13.81M
-297.98%		-17.72M
-28.31%		-22.17M
-25.11%		N/A
8.58%		N/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
GANX ebit by date.GANX ebit by date.
-13.83M
-297.41%		-17.78M
-28.56%		-22.253M
-25.16%		-22.651M
8.55%		-19.772M
2.84%		-27.658M
-39.89%		-30.88M
-11.65%		-36.133M
-17.01%		8.609M
123.83%		72.737M
744.89%		143.06M
96.68%		198.93M
39.05%		336.63M
69.22%
Operating Margin
GANX operating margin by date.GANX operating margin by date.
-8,643.75%-12,700.00%-40,313.59%N/AN/AN/AN/AN/A16.48%52.99%61.98%65.60%70.41%
EPS
YoY % growth
GANX eps by date.GANX eps by date.
-1.51-1.48
1.99%		-1.78
-20.27%		-0.98
48.31%		-0.66
28.49%		-0.72
-10.19%		-0.93
-27.89%		-1.18
-27.61%		-0.36
69.83%		-0.361.69
574.29%		3.90
130.12%		N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-0.15
-34.45%		-0.16
0.12%		-0.17
12.32%		-0.18
-22.40%		-0.21
-40.23%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-5.242M
-57.38%		-5.646M
-29.21%		-6.011M
-18.11%		-6.996M
-28.94%		-8.091M
-54.33%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

GANX Yearly Revenue VS EstimatesGANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2029 2030 2031 2032 2033 100M 200M 300M 400M
GANX Yearly EPS VS EstimatesGANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-0.26%
EPS Next 5 Year
10.02%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

GAIN THERAPEUTICS INC / GANX Forecast FAQ

What do analysts expect the price target to be for GAIN THERAPEUTICS INC (GANX)?

11 analysts have analysed GANX and the average price target is 7.75 USD. This implies a price increase of 278.24% is expected in the next year compared to the current price of 2.0495.

When does GAIN THERAPEUTICS INC (GANX) report earnings?

GAIN THERAPEUTICS INC (GANX) will report earnings on 2026-03-19, after the market close.

Can you provide the consensus estimates for GAIN THERAPEUTICS INC next earnings?

The consensus EPS estimate for the next earnings of GAIN THERAPEUTICS INC (GANX) is -0.15 USD and the consensus revenue estimate is 0 USD.